EGFR and non-small cell lung carcinoma: Finally, the third study to complete was the lung cancer trial (NCT00994123; Figure 7a), in which patients with EGFR wild-type NSCLC were randomized 2:1 to receive seribantumab in combination with erlotinib at a dose of 100 mg/day, or erlotinib alone at 150 mg/day.